Evidence map›Paper›PMID 31937596›Full record

Observational studyNeurology(R) neuroimmunology & neuroinflammation2020

Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study.

Lara Diem, Ariadne Daponte, Oliver Findling, Andrei Miclea, Myriam Briner, Anke Salmen, Ralf Gold, Constantinos Kilidireas, Andrew Chan, Maria Elftheria Evangelopoulos and 1 more

Open access · goldAbstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Lara DiemFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Ariadne DaponteFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Oliver FindlingFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany. oliver.findling@ksa.ch.
Andrei MicleaFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Myriam BrinerFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Anke SalmenFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Ralf GoldFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Constantinos KilidireasFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Andrew ChanFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Maria Elftheria EvangelopoulosFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Robert HoepnerFrom the Department of Neurology (L.D., A.M., M.B., A.S., A.C., M.E.E., R.H.), Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, Bern, Switzerland; Department of Neurology (A.D., C.K., M.E.E.), Eginition University Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (O.F.), Cantonal Hospital Aarau, Tellstrasse, Aarau, Switzerland; Department of Neurology (O.F.), Karl Landsteiner University of Health Sciences, Site Tulln, Austria; and Department of Neurology (R.G.), St. Josef Hospital Ruhr University Bochum, Germany.
Kantonsspital Aarau · CHEginition Hospital · GRKarl Landsteiner University of Health Sciences · ATNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDespite frequent use of fingolimod (FTY) and dimethyl fumarate (DMF), studies comparing clinical efficacy and withdrawal rates of DMF and FTY concerning different pretreatment situations are rare. The aim of our study was to compare relapse occurrence and withdrawal rates of DMF and FTY in different pretreatment situations.

methodsPatients from 4 European centers were retrospectively identified and followed until the 1st relapse after treatment start or if no relapse occurred for a maximum of 2 years. Cox regression analyses adjusted for relapsing-remitting MS (RRMS) disease duration, sex, and region were performed for the following pretreatment situations: treatment naive or injectables or DMF/FTY or natalizumab.

resultsSeven hundred thirty-two patients with RRMS (female/male: 2.4:1.0; DMF n = 409, FTY n = 323) were analyzed. Compared with FTY-treated patients, DMF-treated patients discontinued treatment more frequently mainly because of side effects (DMF/FTY: 29.3%/20.7%). Clinical relapses occurred in 24.5% of the patients within 24 months. Survival analysis demonstrated that compared with FTY treatment, DMF treatment was associated with an adjusted hazard ratio (aHR) for occurrence of relapse of 1.9 (95% CI 1.4-2.6,

conclusionsDMF treatment was associated with higher clinical disease activity compared with FTY treatment. A subgroup analysis suggested beneficial effects of FTY in treatment-naive and patients pretreated with natalizumab.

Indexed as

AdultDimethyl FumarateEuropeFemaleFingolimod HydrochlorideFollow-Up StudiesHumansImmunosuppressive AgentsMiddle AgedMultiple Sclerosis, Relapsing-RemittingOutcome Assessment, Health CareRecurrenceRetrospective StudiesSurvival AnalysisDimethyl FumarateFingolimod HydrochlorideImmunosuppressive Agents

Identifiers

PMID31937596
PMCPMC6984136
OpenAlexW3000016746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.